Data News > Post Market Movers: BioNTech SE Positioned for Growth Amid Oncology Shift: Analyst
- Truist initiates coverage on BioNTech SE in collaboration with Pfizer Inc
- Blue-chip stocks offer stable income and capital appreciation
- Pfizer's bladder cancer therapy shows positive results in late-stage study
- Sasanlimab in combination with BCG improves event-free survival in high-risk bladder cancer patients
BioNTech SE, a renowned COVID-19 vaccine manufacturer partnered with Pfizer Inc, has been identified as a promising investment opportunity by Truist. This coverage comes at a time when investors are looking to maximize returns through a combination of consistent income and capital appreciation. High-yield blue-chip stocks are often favored by those seeking stability and yield in their investment portfolios.
In other news, Pfizer has reported positive results from a late-stage study on its experimental treatment for bladder cancer. The therapy showed significant improvements in preventing cancer recurrence and other complications, marking a milestone in cancer research. Additionally, Pfizer's sasanlimab, when used in combination with BCG, has shown promising results in improving event-free survival in high-risk non-muscle invasive bladder cancer patients. This development is a significant step forward in the treatment of this type of cancer.
Overall, the collaboration between BioNTech SE and Pfizer Inc, along with Pfizer's advancements in bladder cancer therapy, indicate a strong potential for growth in the healthcare sector. Investors may want to keep a close eye on these developments as they could have a meaningful impact on the stock performance of both companies in the near future.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Post Market Movers: BioNTech SE Positioned for Growth Amid Oncology Shift: Analyst
By KlickAnalytics Data Insights | January 10, 2025 08:09PM ET
Key Points
- Truist initiates coverage on BioNTech SE in collaboration with Pfizer Inc
- Blue-chip stocks offer stable income and capital appreciation
- Pfizer's bladder cancer therapy shows positive results in late-stage study
- Sasanlimab in combination with BCG improves event-free survival in high-risk bladder cancer patients
BioNTech SE, a renowned COVID-19 vaccine manufacturer partnered with Pfizer Inc, has been identified as a promising investment opportunity by Truist. This coverage comes at a time when investors are looking to maximize returns through a combination of consistent income and capital appreciation. High-yield blue-chip stocks are often favored by those seeking stability and yield in their investment portfolios.
In other news, Pfizer has reported positive results from a late-stage study on its experimental treatment for bladder cancer. The therapy showed significant improvements in preventing cancer recurrence and other complications, marking a milestone in cancer research. Additionally, Pfizer's sasanlimab, when used in combination with BCG, has shown promising results in improving event-free survival in high-risk non-muscle invasive bladder cancer patients. This development is a significant step forward in the treatment of this type of cancer.
Overall, the collaboration between BioNTech SE and Pfizer Inc, along with Pfizer's advancements in bladder cancer therapy, indicate a strong potential for growth in the healthcare sector. Investors may want to keep a close eye on these developments as they could have a meaningful impact on the stock performance of both companies in the near future.
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.